Psychedelics and Neurostimulation for Brain Rewiring: Depression, PTSD, and the Science of Recovery

Depression is not simply a problem of feeling sad. It can disrupt attention, motivation, physical health, relationships, and a person’s ability to use the very tools intended to help them recover. In its most severe forms, it also creates an urgent medical problem: someone needs relief now, not several weeks from now.

That urgency is driving a different approach to psychiatric treatment. Rather than focusing only on neurotransmitter levels or the content of someone’s thoughts, researchers are asking whether they can change the activity and coordination of specific brain circuits.

In my discussion with Dr. Nolan Williams, a central theme emerged: a brain circuit that is stuck in an unhealthy pattern may still be capable of being recalibrated. Transcranial magnetic stimulation, accelerated neuromodulation, and psychedelic-assisted therapies offer different ways of investigating that possibility. Their promise is substantial, but so are the distinctions between established findings, preliminary results, and compelling anecdotes.

Table of Contents

• Why Depression Requires Both Better and Faster Treatments
• The Brain-Heart Connection Is Physical, Not Metaphorical
• TMS and the Restoration of Cognitive Control
• SSRIs Work, but the Chemical Imbalance Story Is Incomplete
• Trauma, Psychedelics, and the Possibility of Updating Old Rules
• MDMA, Psilocybin, and Ketamine: Different Evidence, Different Timelines
• Psilocybin and TMS May Converge on Related Brain Networks
• Ibogaine: Life Review, Preliminary Findings, and Cardiac Risk
• Ayahuasca: A Two-Plant Combination With Complex Effects
• SAINT and Stanford Neuromodulation Therapy: Reorganizing Treatment in Time
• A More Hopeful Framework, Without Abandoning Caution

Why Depression Requires Both Better and Faster Treatments

Williams described depression as a leading source of disability worldwide. Its effects also extend beyond psychiatric symptoms. Depression can increase vulnerability to other illnesses and worsen the course of existing medical and psychiatric conditions.

The relationship with cardiovascular health is particularly important. Depression is recognized as a cardiovascular risk factor, underscoring that mental and physical health are not separate systems.

Yet the speed of psychiatric treatment has often lagged behind the urgency of the illness. Someone hospitalized with severe depression may receive the same oral antidepressant they were already taking outside the hospital. Those medications can help, but they generally do not produce their full therapeutic effects immediately.

Williams’ training in neurology and psychiatry made that contrast especially striking. Neurology has ways to intervene rapidly in acute brain problems. His research asks whether psychiatry can develop similarly targeted, brain-based interventions for people in crisis.

The Brain-Heart Connection Is Physical, Not Metaphorical

The connection between the mind and heart can sound abstract. Transcranial magnetic stimulation, or TMS, provides a way to probe that connection directly.

TMS uses a changing magnetic field to induce electrical current in brain tissue. Applied over a particular region, it can activate neurons near the brain’s surface without surgically implanting an electrode. The National Institute of Mental Health’s overview of brain stimulation therapies provides additional context on this broader treatment category.

One important target is the dorsolateral prefrontal cortex, a region involved in cognitive control. It helps regulate how we respond to information, emotion, and competing demands.

Stimulating this region can influence a connected network that includes the anterior cingulate cortex, insula, and amygdala. Through downstream pathways involving the nucleus tractus solitarius and vagus nerve, that activity can reach the heart.

Williams described experiments in which stimulation over relevant prefrontal regions produced measurable slowing of heart rate. Comparable stimulation over visual or motor cortex did not produce the same pattern. That specificity matters: it suggests a particular circuit connection, not simply a general response to having the brain stimulated.

TMS and the Restoration of Cognitive Control

A useful way to think about one model of depression is that the normal relationship between regulatory and emotional systems becomes disrupted.

The prefrontal cortex is something like a coach. Deeper systems involved in emotional salience and conflict detection are like players. In a well-regulated system, the coach helps organize the game. In depression, those deeper systems can exert excessive influence, while the prefrontal cortex does not provide sufficient regulation.

This is a simplifying analogy, not a complete explanation of depression. But it captures the treatment goal: restore more effective coordination rather than erase emotion.

Williams described TMS as a form of exercise for a targeted brain region. Repeated stimulation provides a physiologically meaningful signal intended to strengthen the region’s regulatory role. In his work, changes in the timing and relationship between the left dorsolateral prefrontal cortex and cingulate regions correlated with antidepressant improvement.

Why Biological Treatment Can Make Psychotherapy More Accessible

One of the most important clinical observations was that people sometimes became better able to use psychotherapy after their depression improved with TMS.

Some patients had previously been told they were not trying hard enough in therapy. After treatment, they returned to their therapy materials and found that the ideas finally made sense or became usable.

That is a very different interpretation of treatment difficulty. A person’s inability to apply a psychological tool does not necessarily reflect a lack of effort. Severe depression may interfere with the cognitive functions needed to benefit from it.

Williams also described a small number of patients who reported unusually strong experiences of present-moment awareness after rapid symptom improvement. Several independently described sitting at the beach and feeling fully present in a way they had previously only read about in mindfulness books.

Those reports are interesting, but they remain anecdotes. They do not establish that TMS reliably produces mindfulness or that such experiences explain its antidepressant effects.

SSRIs Work, but the Chemical Imbalance Story Is Incomplete

Selective serotonin reuptake inhibitors, or SSRIs, can be effective treatments. Williams emphasized that evidence supports their benefit for a subset of people with depression, obsessive-compulsive disorder, generalized anxiety disorder, and panic symptoms.

Rejecting an overly simple explanation of depression does not mean rejecting medications that help people.

The difficulty lies in equating an SSRI’s action on serotonin signaling with proof that depression is caused by a serotonin deficiency. SSRIs alter serotonin availability relatively quickly, while their clinical benefits typically take longer. That delay suggests that downstream changes, potentially including changes in plasticity, are important.

A treatment can work without validating the original theory used to explain why it works.

From Personal History to Chemistry to Circuits

Williams organized this shift using three broad frameworks:

• Psychiatry 1.0: An emphasis on personal history, family relationships, and psychological interpretation.
• Psychiatry 2.0: An emphasis on chemical imbalance and medication-based correction.
• Psychiatry 3.0: An emphasis on brain circuits, their dynamics, and their capacity to change.

These are conceptual categories, not strict historical divisions. Experiences, neurotransmitters, and circuits all matter. The value of the circuit framework is that it directs attention toward a system that may be modifiable.

TMS is a particularly clear example because it can change symptoms without administering a drug. Ketamine and psilocybin offer another perspective: researchers can examine circuit changes that remain after the immediate drug effects have ended.

For patients, that framing can be empowering. It does not imply that they are permanently broken, missing an essential chemical, or forever trapped by an early experience. It also does not guarantee permanent recovery. Some people relapse and require additional treatment. The point is that recurrence need not erase the evidence that a healthier state is possible.

Trauma, Psychedelics, and the Possibility of Updating Old Rules

Why would the brain hold onto a response that makes life worse?

One answer is that a response can be adaptive in one setting and harmful in another. A veteran who reacts to a sudden loud noise by immediately taking cover may be expressing a response that was protective in combat. The same response can be disruptive and distressing in a safe civilian environment.

The brain has retained a rule after the context that made the rule useful has changed.

One hypothesis behind psychedelic-assisted therapy is that these substances create a period of heightened plasticity in which a person can revisit memories, beliefs, or emotional responses differently. Re-experiencing and reconsolidating a memory in that state might help change its subsequent impact.

That is a proposed mechanism, not a settled explanation. Williams’ position was pragmatic: if carefully designed trials show that a treatment helps, it deserves consideration. If they do not, cultural enthusiasm is not enough.

MDMA, Psilocybin, and Ketamine: Different Evidence, Different Timelines

These compounds are often discussed together, but their clinical evidence and treatment patterns should not be treated as interchangeable.

MDMA-Assisted Therapy for PTSD

The MDMA studies discussed focused on PTSD in controlled clinical settings, with medical screening and structured therapeutic support.

Williams summarized the early trial results as showing clinically meaningful improvement in roughly two-thirds of participants. In some earlier follow-up studies, benefits appeared to persist for years in some people.

That is encouraging, particularly for people with substantial PTSD symptoms. But the result belongs to a treatment protocol, not merely to a substance taken in isolation. A small number of supervised drug sessions within a clinical program is not equivalent to unsupervised use.

Psilocybin for Depression

For psilocybin, the discussion centered on depression. Williams described improvement in approximately half to two-thirds of participants in open-label studies, with results varying according to treatment resistance. In the blinded trials he discussed, the proportion improving was closer to one-third.

Those figures should not be read as a single universal success rate. Open-label studies and blinded trials differ in important ways, including what participants know about their treatment. Patient populations and definitions of improvement also differ.

The distinction between improvement and remission is equally important. A meaningful reduction in symptoms does not necessarily mean that symptoms have fully resolved.

Ketamine and the Question of Durability

Williams contrasted these findings with ketamine, noting that the antidepressant benefit of a single infusion lasts, on average, around a week and a half in the work he discussed.

Some people therefore require repeated treatment. Others receive a series of doses and experience a longer benefit afterward.

This highlights a central question across rapid-acting treatments: producing relief and maintaining relief are related, but separate, challenges.

These figures reflect the studies discussed in our conversation, rather than a comprehensive current comparison of treatment effectiveness or regulatory status.

Psilocybin and TMS May Converge on Related Brain Networks

Early psychedelic imaging work by researchers including David Nutt and Robin Carhart-Harris challenged an intuitive assumption. A subjectively intense psychedelic experience did not simply correspond to a uniform increase in brain activity. Some measurements instead showed decreases in activity alongside substantial changes in connectivity.

Activity and connectivity are different. A region can become less active while the pattern of communication across regions becomes more globally integrated.

Williams highlighted a potentially important overlap between psilocybin and his TMS work: changes in connectivity between the subgenual anterior cingulate cortex and the default mode network.

The default mode network is involved in aspects of self-related processing. In the model he described, excessive coupling between systems involved in negative mood and systems involved in self-representation may help explain why depression can feel inseparable from one’s identity.

Effective treatment appeared to reduce that coupling. In simplified terms, negative emotional processing became less tightly linked to the brain’s representation of the self.

This is an intriguing point of convergence, not proof that TMS and psilocybin work identically. It suggests that very different interventions may sometimes influence overlapping circuit relationships.

Ibogaine: Life Review, Preliminary Findings, and Cardiac Risk

Ibogaine is an alkaloid found in the root bark of the iboga plant, associated with traditional use in Gabon, Africa.

People describe its effects differently from those of many other psychedelics. With eyes closed, some report revisiting earlier memories with a sense of distance and empathy, both for themselves and for others. These experiences are often described as a life review.

They can also be prolonged. Williams described experiences lasting around 24 to 36 hours in some individuals, with duration varying according to metabolism and other factors. The process was characterized as demanding rather than recreational.

What the Research Was Measuring

Williams described work evaluating former special operations personnel, including Navy SEALs and Army Rangers, before and after ibogaine exposure. The assessments included:

• Depression and PTSD symptom scales.
• Executive function and verbal memory testing.
• Brain imaging.
• Electroencephalography, or EEG.

At the time of the discussion, the data had not been fully analyzed. Reports of dramatic improvement therefore remained preliminary.

One recurring theme was moral injury: distress related to actions or events that violate a person’s moral framework. Some participants described becoming able to view themselves with empathy and forgive themselves for events connected to military service.

Those accounts are meaningful, but they do not substitute for a completed clinical analysis.

Why the Safety Concerns Are Central

Ibogaine carries serious cardiac risk. Williams emphasized that this risk has limited its study. Cardiac screening, including electrocardiograms, was part of the research approach he described.

Screening may reduce risk; it does not establish that the substance is broadly safe. The possibility of a powerful therapeutic experience cannot be separated from the need to evaluate its medical hazards.

Ayahuasca: A Two-Plant Combination With Complex Effects

Ayahuasca is used in ceremonial and religious settings in parts of South America, including Brazil, Peru, Ecuador, and Colombia. Its pharmacology depends on combining plants with complementary actions.

One component supplies dimethyltryptamine, or DMT. Another supplies compounds that reversibly inhibit monoamine oxidase, an enzyme involved in breaking down DMT in the digestive system. That inhibition allows orally consumed DMT to reach the brain in amounts capable of producing psychedelic effects.

The important principle is that the combination changes what the individual components can do. It also means that safety depends on the combination and its interactions, not simply on whether each ingredient is plant-derived.

Williams discussed antidepressant research and observational work examining neurocognitive outcomes in religious communities using ayahuasca. He described reassuring findings in those particular settings. Such findings should not be generalized into a claim that ayahuasca is safe for everyone or safe alongside psychiatric medications.

The Brazilian Prisoner Example

Williams also recounted a Brazilian prisoner study in which people exposed to ayahuasca reportedly had a statistically lower rate of returning to prison than a comparison group receiving an inert substance.

Important details were not established in the discussion, including the exact offenses and the broader context of the intervention. The example is therefore best understood as a question for further investigation, not as a basis for recommending ayahuasca in correctional settings.

Williams explicitly cautioned against that leap. The scientific question is whether a profound change in perspective can influence later behavior, and how researchers could responsibly determine what caused that change.

SAINT and Stanford Neuromodulation Therapy: Reorganizing Treatment in Time

One of the most concrete examples of circuit-based treatment is Stanford Accelerated Intelligent Neuromodulation Therapy, originally called SAINT and subsequently referred to as Stanford Neuromodulation Therapy, or SNT.

The key distinction is between the device and the treatment. A TMS device delivers stimulation. The therapeutic protocol specifies where to stimulate, which stimulation pattern to use, how much to deliver, and when to repeat it.

Changing the protocol can therefore matter enormously, even when the underlying technology remains TMS.

Using Spaced Learning to Design Stimulation

Traditional TMS schedules commonly involved one session per day, five days per week, for approximately six weeks. Williams’ group asked whether principles of spaced learning could make stimulation more efficient.

Consider reviewing a set of flashcards and returning to the same material about an hour later. The interval between repetitions can influence learning. The idea was to apply a related timing principle to repeated stimulation of a brain circuit.

The accelerated protocol described in our discussion involved:

• Ten sessions per day, spaced approximately an hour apart.
• Five treatment days, creating 50 sessions across the course.
• About 90 minutes of actual stimulation per day, distributed within a much longer daily treatment schedule.
• A substantially higher total stimulation dose than a conventional course.

This was not simply six weeks of treatment compressed into five days. The approach also increased the overall dose, based partly on observations that some patients continued improving when conventional TMS was extended.

Rapid Remission and the Remaining Durability Problem

Across the open-label work and trials discussed, Williams reported remission rates ranging roughly from 60% to 90%, with improvement occurring within one to five days. The range reflects different study settings and should not be interpreted as a guaranteed outcome for an individual.

Remission here meant reaching a level of symptoms consistent with a normal mood range, rather than simply feeling somewhat better.

Durability varied. Some people needed further stimulation. Others experienced remission lasting a year or longer, with individual reports extending to several years.

Williams also described patients reporting that they felt normal again without ongoing subjective side effects. Those reports are encouraging, but they are not a claim that every patient will have no adverse effects.

The major remaining task is to determine how best to maintain recovery: who needs retreatment, when it should occur, and how to optimize the dose and schedule.

A More Hopeful Framework, Without Abandoning Caution

The most important idea connecting these treatments is not that one device or compound will solve every psychiatric illness. It is that severe symptoms can arise from brain systems capable of meaningful change.

That perspective makes room for medication, psychotherapy, neuromodulation, and carefully studied psychedelic-assisted approaches without insisting that they compete for a single explanation of depression.

It also requires discipline. Brain imaging findings are not the same as clinical recovery. Anecdotes are not controlled trials. Rapid improvement is not necessarily lasting remission. A powerful experience is not automatically a therapeutic one.

Williams argued that psychedelic research should be evaluated without either countercultural romanticism or reflexive dismissal. If these substances prove useful, their place is within carefully protected treatment settings, with screening, supervision, and attention to risk.

The hopeful message is that a person can become well without having to conclude that they were never truly ill. Depression and trauma-related symptoms can be profoundly disabling, while the systems sustaining them may still be changeable. The scientific task is to learn how to produce that change reliably, safely, and for as long as possible.